

***Astragalus* extract inhibits proliferation but enhances apoptosis in gastric cancer**

Zhengguang Wang^{1,2*}, Liuyi Dong², Yinan Zhen², Yanan Wang², Dongjiang Qi¹, Aman Xu¹, Xiangling Meng² and Weiping Li^{2*}

¹Department of Surgery, First Affiliated Hospital of Anhui Medical University, Anhui, Hefei, China

²Department of Pharmacology, Key Laboratory of Antiinflammatory and Immunopharmacology, Ministry of education; Key Laboratory of Chinese Medicine Research and Development, State Administration of Traditional Chinese Medicine; Anhui Medical University, Hefei, Anhui, China

Abstract: We and others have shown that *Astragalus* extract (AE) regulates various cellular processes including inflammation and apoptosis. It remains elusive whether and how AE modulates apoptosis in gastric cancer cells *in vitro* and *in vivo*. The objective of this study is to determine the effects and mechanisms of AE on the proliferation and apoptosis of human gastric cancer SGC-7901 cells and on tumor growth in orthotopic transplantation gastric tumor model in nude mice. Human gastric adenocarcinoma SGC-7901 cells and nude mice implanted with gastric cancer cells were treated with different concentration of AE and 5-fluorouracil as control. Cellular proliferation, apoptosis and tumor growth as well as interleukin (IL)-6/signal transducer and activator of transcription (Stat) 3 signals pathway were determined. We found that AE inhibited proliferation but caused apoptosis in human gastric cancer cells. Furthermore, the tumor growth and volume were reduced by AE administration in nude mice implanted with gastric cancer cells. In addition, treatments with AE decreased the expression of Bcl-2 proteins, whereas the expression of Bax was increased after AE treatment in tumor tissues of nude mice transplanted with human gastric cancer cells. This was associated with AE-mediated reduction of IL-6, phosphorylated Stat3, survivin and vascular endothelial growth factor. Overall, AE enhances apoptosis in gastric cancer cells *in vitro* and *in vivo*, which is associated with decreased activation of IL-6/Stat3 signals.

Keywords: *Astragalus* extract, gastric cancer, apoptosis, STAT3, IL-6, vascular endothelial growth factor, surviving.

INTRODUCTION

Gastric cancer is the second leading cause of cancer-related deaths with high recurrence rate (Ezzati, Henley *et al.*, 2005). There is no significant improvement for the overall survival rate of gastric cancer and few novel chemopreventive approaches have been developed for this disease (Delaunoy, 2011). This is associated with the incomplete understanding of signaling pathways for tumorigenesis and metastasis of gastric cancer. The apoptosis-inducing compounds have been shown to regulate cancer cell proliferation, which is considered a promising approach for treating cancer (Qiao and Wong, 2009, Wu, Nie *et al.*, 2009). Hence, the agents bearing ability to cause apoptosis will be the promising therapeutic ways in inhibiting tumorigenesis and tumor recurrence. Signal transducer and activator of transcription 3 (Stat3) is a transcription factor and it can be activated by a variety of growth factors and cytokines (i.e., interleukin [IL]-6) through tyrosine phosphorylation. For instance, IL-6/IL-6R complex associates with glycoprotein 130, which can activate Stat1 and Stat3 through the signals mediated from the Janus-associated kinase during neoplastic growth (Aaronson and Horvath, 2002, Leu, Wong *et al.*, 2003). Upon activation, Stat3 is

recruited on the promoters of the targeted genes (e.g., cyclin D1, Bcl-2, Bcl-xL, matrix metalloproteinases and vascular endothelial growth factor [VEGF]), leading to increased transcription of these genes (Buettner, Mora *et al.*, 2002, Niu, Wright *et al.*, 2002, Gamero, Young *et al.*, 2004). Therefore, targeting IL-6/Stat3 signal pathway may be beneficial to gastric cancer via apoptosis induction.

Astragalus is one of the Chinese tonic herbs, and its active components include astragalosides, flavonoids, and polysaccharides, which are extracted from the root of *Astragalus membranaceus* (Fisch) Bge (Sinclair, 1998, Zheng, Liu *et al.*, 1998). We and others have shown that astragalosides are able to regulate a variety of cell processes including aging, immune, inflammation, oxidative stress, host defense, and cell metabolism (Lei, Wang *et al.*, 2003, Yin, Li *et al.*, 2010, Ghafourian Boroujerdnia, Azemi *et al.*, 2011, Qu, Yang *et al.*, 2012, He, Du *et al.*, 2013, Liu, Qin *et al.*, 2013, Yang, Qu *et al.*, 2013). Accumulating evidence has revealed that *Astragalus* inhibits proliferation but induces apoptosis in cancer cells *in vitro* and *in vivo* (Chen, Xie *et al.*, 2005, Cho and Leung, 2007). Sporadic reports have shown that *Astragalus* affects proliferation, invasion and apoptosis in gastric cancer cells (Auyeung, Woo *et al.*, 2012, Wang, Xuan *et al.*, 2013). However, it remains elusive whether

*Corresponding authors: wangzhengguang@ahmu.edu.cn, lwp19@126.com

and how astragalus has any effect on gastric cancer through IL-6/Stat3 signals. We hypothesize that astragalus has an inhibitory effect on gastric cancer via regulation of IL-6/Stat3 signal pathway. To test this hypothesis, we employed *in vitro* in human gastric adenocarcinoma SGC-7901 cells and *in vivo* in nude mice implanted with gastric cancer cells, which were treated with astragalus extracts (AE). The molecular components of IL-6/Stat3 pathway were also determined in mice administered with AE.

MATERIALS AND METHODS

Reagents

Astragalus extract containing astragalosides >63% with brown powder was purchased from the Guizhou Hanfang Pharma Co., Ltd (batch number: 19993254, Guiyang, Guizhou, China) and was extracted with 95% ethanol solvents from the root of *Astragalus membranaceus* (Fisch) Bge. Quality control was performed using high-performance liquid chromatography coupled with diode array and evaporative light scattering detectors. 5-FU was purchased from the Tianjin Kingyork Group Co., Ltd (Tianjin, China), and CDDP was obtained from the Qilu Pharmaceutical Co., Ltd (Jinan, Shandong, China).

Cell culture and treatment

Human gastric adenocarcinoma SGC-7901 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Beijing), and cultured in DMEM Medium with FBS (10%) at 37°C in a humidified atmosphere with 5% CO₂. Cells were split every 2-3 days via trypsinization, and fresh culture medium were added (Wang, Li *et al.*, 2012). The SGC-7901 cells were treated with AE (100, 50, 25 µg/ml) and 5-FU (10 µg/ml) as a control for 3 days. The medium and reagents were changed daily until apoptosis analysis.

Morphological measurement of apoptosis

The morphological change of apoptosis was assayed under fluorescence microscope after Hoechst33258 staining. Briefly, cells were fixed in ethanol followed by Hoechst33258 (10µg/ml) staining for 30min at 37°C, then visualized under the UV fluorescence microscope. Apoptotic cells were considered as cells showing nuclear and cytoplasmic shrinkage, chromatin condensation and apoptosis body. At least 400 cells were counted, and the percentage of apoptotic cells (Apoptotic Index) was calculated (Wu, Sun *et al.*, 2001).

Cell proliferation by MTT assay

Sterile MTT dye (100µl of 0.5mg/ml, Amresco, Solon, OH, USA) was added to SGC-7901 cells cultured on 96-well plates for 4 h at 37°C. The culture medium was then removed followed by the addition of dimethyl sulphoxide (150 µl, Sigma, St. Louis, MO, USA). The absorbance was determined at 570 nm using a spectrophotometer. All experiments were performed for three times (Na, Liu *et*

al., 2009, Lin, Dai *et al.*, 2010). The inhibitory rate of cell proliferation was calculated using the formula $([OD \text{ of control} - OD \text{ of treatment}] / OD \text{ of control}) \times 100\%$.

Mice and orthotopic implantation of gastric cancer cells

All BALB/c nude mice (male, 5-6 weeks old) were purchase from the Laboratory Animal Center of the Academy of Military Medical Sciences (Beijing, China), and underwent implantation of gastric cancer cells (SGC-7901) (Djokovic, Trindade *et al.*, 2010). Briefly, The SGC-7901 cells (nearly 70-80% confluence) were harvested via trypsinization, and cell viability was assessed using the trypan blue exclusion test. Cells with >90% viability were subcutaneously injected in both rear flanks (3×10^6 cells/0.1ml/flank). Tumor nodules occurred ~8-10 days following cell injection, and these mice were treated with AE and 5-FU for 3 weeks once tumor volume reached 100-300mm³. The tumor size and weight were measured. The tumor volume (V) (mm³) was measured with the following formula $V = 0.52 \times a \times b^2$ (a and b refer to the corresponding longer and shorter diameter of the tumor) (Djokovic, Trindade *et al.*, 2010). No animal death was observed during tumor growth. All animals were treated under protocols approved by the Animal Research Committee of the Anhui Medical University at Hefei, China.

Drug administration

After tumor volume reached 100-300 mm³, mice were then randomly grouped for the following four treatments: saline control, 5-FU (50 mg/kg, twice a week, i.p.), AE (120 mg/kg, daily, i.g.) and AE (60mg/kg, daily, i.g.). These drugs were administered into mice for 3 weeks, and sacrificed for endpoint measurement as described below. The dose of 5-FU was used as per the previous report (Tao, Yang *et al.*, 2015). According to previous reports (Krašteva, Nikolova *et al.*, 2004, Ko, Lam *et al.*, 2005) and our preliminary data (not shown), there are no toxicities found at the dose of 120mg/kg body weight of AE in mice and the doses used here are physiologically reasonable.

Measurement of IL-6 and VEGF by ELISA

Mouse blood was harvested, and serum was isolated through the centrifuged at 1000g for 10min. The levels of IL-6 and VEGF in serum were measured using their corresponding ELISA kits from the R&D System (Minneapolis, MN) following the manufacture's instruction. In brief, ELISA plates were coated with a capture antibody overnight, and then the serum sample or the standards were added for 2 h at room temperature. Each well was added with the biotinylated antibodies for VEGF and IL-6 for 1 h incubation, and washed three times at room temperature. Streptavidin-horseradish peroxidase reagent was added to each well following by addition of substrate solution containing hydrogen

peroxide and tetramethylbenzidine. Finally, stop solution was added, and concentrations were determined at 450 nm based on a standard curve using a microplate reader (Molecular Devices, Sunnyvale, CA, USA).

Flow cytometric analysis of apoptosis

After treatments, SGC-7901 cells were washed twice with cold PBS, and fixed by methanol (2mL) for 30min at 4°C. After cells were fixed, the mixture was added with propidium iodide solution (0.5mL, 100 µg/ml, Sigma) and RNase A (0.5 mL, 0.25 mg/ml, Sigma, St. Louis, MO, USA) for 30 min incubation at room temperature. Cells were resuspended in 1mL PBS and then assessed by flow cytometry with excitation 488 nm and emission >630 nm (Coulter, Brea, CA, USA) as per the manufacturer's instructions (Na, Liu *et al.*, 2009, Lee, Lee *et al.*, 2010). The cells in the subdiploid peak were considered apoptotic.




Fig. 1: Effect of AE and 5-Fu on the apoptosis of human gastric cancer cells detected by Hoechst33258 staining. SGC-7901 cells were treated with AE (100, 50, 25 µg/ml) and 5-FU (10 µg/ml) for 3 days. (A-E) A representative image of morphological change of apoptosis was showed under fluorescence microscope following staining with Hoechst33258. Apoptotic cells were defined as cells showing nuclear and cytoplasmic shrinkage, chromatin condensation and apoptosis body. A: vehicle; B: 25 µg/ml of AE; C: 50 µg/ml of AE; D: 100 µg/ml of AE; E: 10 µg/ml of 5-FU. Original magnification ×200. (Bottom panel) At least 400 cells were counted and the percentage of apoptotic cells was calculated. Data are expressed as the mean ± SD. ** $P < 0.01$, vs. control group.

Immunohistochemistry

The primary gastric specimens from gastrectomy were fixed with formalin, and paraffinized for the preparation of tumor xenograft sections (5 µm thick). For staining, tissue sections were deparaffinized with xylene, and incubated with the reduced concentrations of ethanol followed by the process of antigen unmasking using sodium citrate buffer (10mmol/L). Tissue sections were incubated with 3% hydrogen peroxide in methanol for 10 min to quench the endogenous peroxidase activity prior to blocking with 1% goat serum for 15 min. Tissue samples were then incubated with primary antibodies (anti-Bax, anti-Bcl-2, anti-IL-6, anti-VEGF, and anti-Survivin,

Beijing Zhongshan Jinqiao Biotechnology Co., Ltd, Beijing, China) overnight at 4°C. Negative controls were tissue sections immunostained with nonspecific IgG antibody. The slides were washed in PBS, incubated with biotinylated anti-mouse and anti-rabbit antibodies (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd, Beijing, China) and incubated with streptavidin-peroxidase according to the manufacturer's instructions. 3,3'-diaminobenzidine was used for development, and tissue sections were counterstained with haematoxylin. Finally, the sections were dehydrated in graded ethanol and embedded and the slides were observed under a bright-field microscope. The mean optical density (OD) value of all images was analyzed for the relative levels of protein expression (Wang, Si *et al.*, 2013).




Fig. 2: Effect of AE and 5-Fu on the apoptosis of human gastric cancer cells detected by flow cytometry. SGC-7901 cells were treated with AE (100, 50, 25 µg/ml) and 5-FU (10 µg/ml) for 3 days. (A-E) Apoptosis was determined by flow cytometry with excitation 488 nm and emission >630 nm using propidium iodide staining. Finally, the cells were resuspended in 1 mL PBS and analyzed by flow cytometry with excitation 488 nm and emission >630 nm. The cells in the subdiploid peak were considered apoptotic. A: vehicle; B: 25 µg/ml of AE; C: 50 µg/ml of AE; D: 100 µg/ml of AE; E: 10 µg/ml of 5-FU. (Bottom panel) Apoptosis rate was shown in histogram in SGC-7901 cells treated with AE and 5-FU. Data are expressed as the mean ± SD. ** $P < 0.01$, vs. control group.

Western blot

Cell lysate were prepared using lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 1 mg/L leupeptin, 1 mg/L aprotinin and 1 mM phenylmethylsulfonyl fluoride) on ice followed by the centrifugation at 3000 g for 30 min. Protein concentration in cell lysis was measured using the method of Lowry. Cell lysis were mixed with 4× SDS loading buffer, which was heated for 5min at 95°C. Protein samples (20 µg) were resolved by SDS-PAGE gel, and then transferred onto nitrocellulose membranes (Bio-Rad). TBST buffer containing 5% skimmed milk for 2 h was added to block the membranes and the membranes were incubated with monoclonal antibodies against Bax, Bcl-2, IL-6, p-Stat3, Stat3, VEGF, and surviving (Beijing Zhongshan Jinqiao

Biotechnology Co., Ltd, Beijing, China) overnight. After three time of washing (15 min each), protein levels were assessed using the horseradish peroxidase-linked second antibodies (1:5,000 dilution in 2.5% BSA containing 0.1% Tween (v/v) 20) for 1 h. The bands were visualized using enhanced chemiluminescence method, and membranes were tested for β -actin to confirm equal loading.




Fig. 3: Effect of AE and 5-Fu on the expression of IL-6 in tumor xenografts.

Nude mice implanted with SGC-7901 cells were administered with AE and 5-FU. (A-D) The expression of IL-6 in tumor xenografts was determined using immunohistochemical staining, and the representative images were shown from A to D. A: vehicle; B: 50 mg/kg of 5-FU; C: 60 mg/kg of AE; D: 120 mg/kg of AE. Original magnification $\times 200$. Mean optical density (OD) value of all images was analyzed for relative protein expression levels. (Bottom panel) Protein levels of IL-6 in tumor xenografts were determined using Western blotting. β -actin was a loading control. Relative protein expression of IL-6 was normalized to that of β -actin. Positive immunoreactive bands were quantified densitometrically and expressed as IL-6 in optical density units, respectively. Data are expressed as the mean \pm SD. * $P < 0.05$, ** $P < 0.01$, vs. control group.

STATISTICAL ANALYSIS

Results are shown as mean \pm SE of three experiments. Statistical analysis of significance was calculated with one-way ANOVA followed by Tukey's post hoc test (two-sided) for multigroup comparisons.

RESULTS

Effect of AE on apoptosis and proliferation in gastric cancer cells

In order to determine whether AE treatment has any effect on apoptosis *in vitro*, Hoechst33258 staining and flow cytometry were performed in gastric cancer cells (SGC-7901) treated with AE (100, 50, 25 μ g/ml) for 3 days. As expected, treatment with 5-FU (10 μ g/ml) caused apoptosis in SGC-7901 cells. AE treatment induced apoptosis in a dose-dependent manner in SGC-7901 cells

(figs. 1 and 2). Furthermore, AE treatment caused dose-dependent reduction in proliferation in SGC-7901 cells, which was also observed after 5-FU treatment (table 1). These data suggest that AE treatment causes imbalance of proliferation and apoptosis towards apoptosis in gastric cancer cells.




Fig. 4: Western blot analysis of protein level of p-Stat3 and Stat3 in tumor xenografts in nude mice treated with AE and 5-FU.

Nude mice implanted with SGC-7901 cells were administered with AE and 5-FU. Protein levels of p-Stat3 and Stat3 in tumor xenografts were determined using Western blotting. Relative protein expression of p-Stat3 was normalized to that of Stat3. Positive immunoreactive bands were quantified densitometrically and expressed as p-Stat3 in optical density units, respectively. Data are expressed as the mean \pm SD. ** $P < 0.01$, vs. control group.

Effect of AE on tumor volume and weight in nude mice with implantation of gastric cancer cells

To determine whether AE has an inhibitory effect on the growth of tumor, nude mice were implanted with SGC-7901 cells following by the administration of AE (60 and 120 mg/kg) and 5-FU (50 mg/kg). As expected, administration of 5-FU significantly reduced tumor volume from day 14 to day 21 after implantation of gastric cancer cells. Both doses of AE (60 and 120 mg/kg) treatment significantly reduced tumor volume and tumor weight in mice implanted with gastric cancer cells (tables 2 and 3). These data indicate that AE administration reduces tumor growth in nude mice with implantation of gastric cancer cells.




Fig. 5: Effect of AE and 5-Fu on the expression of Bax and Bcl-2 in tumor xenografts.

Nude mice implanted with SGC-7901 cells were administered with AE and 5-FU. The expression of Bax and Bcl-2 in tumor xenografts were determined using immunohistochemical staining, and the representative images were shown from A to D. A: vehicle; B: 50 mg/kg of 5-FU; C: 60 mg/kg of AE; D: 120 mg/kg of AE. Original magnification $\times 200$. Mean optical density (OD) value of all images was analyzed for relative protein expression levels. Data are expressed as the mean \pm SD. ** $P < 0.01$, vs. control group.

Effect of AE on IL-6-Stat3 signals in tumor xenografts

We and others have shown that IL-6-Stat3 signal plays an important role in the progression and invasion of gastric cancer (Zhu, Chen *et al.*, 2011, Wang, Si *et al.*, 2013, Zhu, Zhang *et al.*, 2014). Hence, we determined the levels and expression of IL-6/Stat3 signals in nude mice implanted with gastric cancer cells in response to AE and chemotherapeutic agents using ELISA, immunohistochemical staining and Western blot. AE administration (60 and 120 mg/kg) reduced the levels of IL-6 in serum of mice implanted with gastric cancer cells (table 4). In tumor xenografts, the expression and level of IL-6 were reduced by the administration of AE and 5-FU (fig. 3). In addition, the phosphorylation of Stat3 was attenuated by AE and 5-FU treatments (fig. 4). These data suggest that the inhibitory effect of AE on tumor growth is associated with decreased activation of IL-6/Stat3 signal.

Effect of AE on apoptosis regulatory proteins in tumor xenografts

Induction of apoptosis by Stat3 signals is one of the major mechanisms for chemotherapeutic agents (Real, Sierra *et al.*, 2002, Wiita, Ziv *et al.*, 2013). Therefore, we determined the expression and levels of Bax (pro-apoptotic) and Bcl-2 (anti-apoptotic) in tumor xenografts of mice treated with 5-FU and AE. As expected, 5-FU treatment increased the expression of Bax in tumor xenografts by immunohistochemical staining (fig. 5). Administration of AE (60 and 120 mg/kg) also induced the expression of Bax in tumor xenografts (fig. 5). In

contrast, the expression of anti-apoptotic proteins Bcl-2 and survivin was reduced by the treatment of 5-FU and AE in tumor xenografts (figs. 6 and 7). Western blots also showed that treatment of 5-FU and AE increased Bax level, whereas Bcl-2 and survivin levels were reduced by these treatments in tumor xenografts of nude mice (figs. 6 and 7). Altogether, AE induces apoptotic response in tumor xenografts of nude mice.




Fig. 6: Effect of AE and 5-Fu on the levels of Bax and Bcl-2 in tumor xenografts.

Nude mice implanted with SGC-7901 cells were administered with AE and 5-FU. Protein levels of Bax and Bcl-2 in tumor xenografts were determined using Western blotting. Relative protein expression of Bax and Bcl-2 was normalized to β -actin. Positive immunoreactive bands were quantified densitometrically and expressed as Bax and Bcl-2 in optical density units, respectively. Data are expressed as the mean \pm SD. * $P < 0.05$, ** $P < 0.01$, vs. control group.

Effect of AE on VEGF in tumor xenografts

Angiogenesis is regulated by pro-angiogenesis factors including VEGF, which is an important hallmark of cancer development (Park, Thomas *et al.*, 2014). Thus, we further determined the expression of VEGF after AE and 5-FU treatments. It was found that the expression and levels of VEGF were reduced by AE and 5-FU treatments (table 4, fig. 8). These data suggest that the inhibitory effect of AE on tumor growth is associated with decreased expression of VEGF.

DISCUSSION

In this study, we demonstrated that the chemo preventive potential of AE against gastric cancer cells by its ability to induce apoptosis *in vitro* in the SGC-7901 cells and *in vivo* in nude mice transplanted with gastric cancer cells. This is in agreement with the previous findings that astragalus inhibits proliferation and induces apoptosis in other cancer cells (Chen, Xie *et al.*, 2005, Cho and Leung, 2007, Tin, Cho *et al.*, 2007, Liu, Chen *et al.*, 2011, Auyeung, Woo *et al.*, 2012, Wang, Xuan *et al.*, 2013, Auyeung, Law *et al.*, 2014). Nevertheless, further study using 5-FU-resistant gastric cancer cells will reveal the chemo sensitizing effects of AE on gastric cancer, despite AE enhanced the chemotherapeutic response to 5-FU in SGC-7901 cells (Wang Z, *et al.* unpublished data).




Fig 7: Effect of AE and 5-Fu on the expression of survivin in tumor xenografts.

Nude mice implanted with SGC-7901 cells were administered with AE and 5-FU. (A-D) The expression of survivin in tumor xenografts were determined using immunohistochemical staining, and the representative images were shown from A to D. A: vehicle; B: 50 mg/kg of 5-FU; C: 60 mg/kg of AE; D: 120 mg/kg of AE. Original magnification $\times 200$. Mean optical density (OD) value of all images was analyzed for relative protein expression levels. (Bottom panel) Protein levels of survivin in tumor xenografts were determined using Western blotting. β -actin was a loading control. Relative protein expression of survivin was normalized to that of β -actin. Positive immunoreactive bands were quantified densitometrically and expressed as survivin in optical density units, respectively. Data are expressed as the mean \pm SD. * $P < 0.05$, ** $P < 0.01$, vs. control group.

IL-6 causes the sustained activation of STAT3, which plays an important role in enhancing invasion of gastric cancer cells through (Lin, Lin *et al.*, 2007, Kinoshita, Hirata *et al.*, 2013). Furthermore, STAT3 activation also leads to growth stimulation, anti-apoptosis, and angiogenesis, and all these processes are linked to inflammation, immunity, and oncogenesis (Aaronson and Horvath, 2002, Bromberg, 2002, Yu, Pardoll *et al.*, 2009). It has been shown that blockade of the JAK/STAT3 signal reduces the growth of human cancers (Toyonaga, Nakano *et al.*, 2003). Recent studies have shown that STAT3 maintains the survival of gastric cancer cells (Kanda, Seno *et al.*, 2004, Sekikawa, Fukui *et al.*, 2008, Jackson and Giraud, 2009, Giraud, Menheniott *et al.*, 2012, Hsu, Hsieh *et al.*, 2012). Furthermore, STAT3 activation is considered as a predictive marker for poor prognosis in human gastric cancer (Yakata, Nakayama *et al.*, 2007, Kim, Cha *et al.*, 2009, Xiong, Du *et al.*, 2012). We found that AE treatment reduced the expression and level of IL-6 and Stat3 phosphorylation in tumor xenografts from nude mice. These findings suggest that the chemo preventive potential of AE is associated with deactivation of IL-6/Stat3 signal pathway.




Fig. 8: Effect of AE and 5-Fu on the expression of VEGF in tumor xenografts.

Nude mice implanted with SGC-7901 cells were administered with AE and 5-FU. (A-D) The expression of VEGF in tumor xenografts was determined using immunohistochemical staining, and the representative images were shown from A to D. A: vehicle; B: 50 mg/kg of 5-FU; C: 60 mg/kg of AE; D: 120 mg/kg of AE. Original magnification $\times 200$. Mean optical density (OD) value of all images was analyzed for relative protein expression levels. (Bottom panel) Protein levels of VEGF in tumor xenografts were determined using Western blotting. β -actin was a loading control. Relative protein expression of VEGF was normalized to that of β -actin. Positive immunoreactive bands were quantified densitometrically and expressed as VEGF in optical density units, respectively. Data are expressed as the mean \pm SD. * $P < 0.05$, ** $P < 0.01$, vs. control group.

It has been shown Stat3 is able to bind to recognition sequence in the promoter of target genes including Bcl-2, survivin and VEGF, thereby increasing their transcription (Buettner, Mora *et al.*, 2002, Niu, Wright *et al.*, 2002, Gamero, Young *et al.*, 2004). Furthermore, angiogenesis blockade is a promising mean to inhibit tumor growth, invasion and metastasis. In the current study, the expression and level of Bcl-2, Bax, and survivin was abnormally altered in gastric cancer, which is redressed by AE administration. Moreover, AE treatment reduced the expression of VEGF in tumor xenografts in mice. These findings implicate that the chemo preventive potential of AE is associated with increased apoptosis and reduced angiogenesis. However, future study is needed to determine whether AE treated alters the recruitment of Stat3 on the promoters of genes including Bcl-2, Bax, VEGF and survivin in gastric cancer.

Radix astragalus membranaceus is commonly used to reduce the side-effects of cytotoxic antineoplastic drugs. This is in agreement with the findings that polysaccharides significant ameliorates the degree of myelosuppression caused by chemotherapeutic drugs in cancer patients (Ma, Shi *et al.*, 2002). Our unpublished

Table 1: Effect of AE on the proliferation of human SGC-7901 cells

Group	Concentration ($\mu\text{g/ml}$)	OD value	Inhibition rate (%)
Control	-	0.549 ± 0.070	-
AE	25	$0.330 \pm 0.033^{**}$	39.4 ± 7.3
	50	$0.306 \pm 0.041^{**}$	44.1 ± 6.5
	100	$0.276 \pm 0.031^{**}$	49.0 ± 8.2
5-Fu	10	$0.228 \pm 0.012^{**}$	58.1 ± 5.1

Statistical analysis of significance was calculated with one-way ANOVA followed by Tukey's post hoc test (two-sided). $^{**}P < 0.01$ compared with control group.

Table 2: Effect of AE on tumor volume in nude mice xenografts with SGC-7901 cells

Group	Dose	Tumor volume (mm^3)						
		0d	3d	7d	10d	14d	17d	21d
Control	—	289.6 ± 79.6	411.4 ± 106.1	767.8 ± 375.0	866.0 ± 408.8	1026.6 ± 328.3	1248.8 ± 416.0	1524.9 ± 465.0
5-Fu (mg/kg)	50	276.5 ± 65.9	331.2 ± 100.4	382.7 ± 115.0	$438.3 \pm 137.2^\dagger$	$572.9 \pm 113.3^{*\dagger}$	$702.8 \pm 98.1^{***}$	$752.2 \pm 254.2^{**}$
AE (mg/kg)	120	276.8 ± 87.2	364.8 ± 65.2	465.3 ± 74.1	$572.6 \pm 87.7^\dagger$	$683.2 \pm 58.1^\dagger$	$811.6 \pm 50.9^{***}$	$998.1 \pm 155.2^{***}$
	60	297.0 ± 36.2	377.7 ± 67.6	471.2 ± 108.2	$586.4 \pm 175.2^\dagger$	$691.5 \pm 153.6^\dagger$	$948.4 \pm 195.2^{***}$	$1134.4 \pm 285.2^{***}$

Statistical analysis of significance was calculated with one-way ANOVA followed by Tukey's post hoc test (two-sided) for multigroup comparisons. $^*p < 0.05$, compared with control group; $^\dagger p < 0.05$, $^{**}p < 0.01$; $^{***}p < 0.001$ compared with day 0.

Table 3: Effect of AE on tumor growth in nude mice xenografts with SGC-7901 cells

Group	Dose	Tumor weight (g)	Inhibitory rate (%)
Control	—	2.41 ± 0.84	-
5-Fu (mg/kg)	50	$1.11 \pm 0.54^*$	53.94
AE (mg/kg)	120	$1.41 \pm 0.38^*$	41.49
	60	1.67 ± 0.97	30.7

Table 4: Effect of AE on the levels of IL-6 and VEGF in the serum of nude mice with SGC-7901 xenograft tumor

Group	Dose	IL-6 (pg/ml)	VEGF (pg/ml)
Control	—	48.7 ± 5.3	123.5 ± 31.7
5-Fu (mg/kg)	50	41.1 ± 8.4	$75.6 \pm 10.6^*$
AE (mg/kg)	120	$34.5 \pm 5.6^{**}$	$90.1 \pm 22.9^*$
	60	$36.5 \pm 3.3^{**}$	108.0 ± 20.6

Statistical analysis of significance was calculated with one-way ANOVA followed by Tukey's post hoc test (two-sided). $^*P < 0.05$, compared with control group

findings showed that AE enhanced the immune function including CD4^+ , CD8^+ and NK cells in patient with gastric cancer. This is corroborated by the study that astragalus attenuates chemotherapy-induced impairment of the immune function in cancer patients (Duan and Wang, 2002). The limitation of the study is to use 5-FU-sensitive SGC-7901 gastric cells, which cannot extrapolate into 5-FU-resistant gastric cancer. Overall, AE is a promising chemo sensitizing agent by enhancing the chemo sensitization in gastric cancer.

In conclusion, the present study provides molecular evidence both *in vitro* and *in vivo* that AE inhibit IL-6/Stat3 signal pathway and thus result in the chemo sensitization of gastric cancer cells to 5-FU-induced tumor growth reduction.

ACKNOWLEDGMENTS

This study was supported by the grant from the Educational Commission of Anhui Province (Grant No. kj2011Z210), Anhui Provincial Natural Science

Foundation (No. 1608085MH182 & 1301043054) and First Affiliated Hospital of Anhui Medical University, Hefei, China.

REFERENCES

- Aaronson DS and Horvath CM (2002). A road map for those who don't know JAK-STAT. *Science*, **296**(5573): 1653-1655.
- Auyeung KK, Law PC and Ko JK (2014). Combined therapeutic effects of vinblastine and astragalus saponins in human colon cancer cells and tumor xenograft via inhibition of tumor growth and proangiogenic factors. *Nutr. Cancer*, **66**(4): 662-674.
- Auyeung KK, Woo PK, Law PC and Ko JK (2012). Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells. *J. Ethnopharmacol.*, **141**(2): 635-641.
- Bromberg J (2002). Stat proteins and oncogenesis. *J. Clin. Invest.*, **109**(9): 1139-1142.
- Buettner R, Mora LB and Jove R (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. *Clin. Cancer Res.*, **8**(4): 945-954.
- Chen L, Xie C and Wu L (2005). Point injection of injectio radici astragali for treatment of post-chemotherapy adverse reactions. *J. Tradit. Chin. Med.*, **25**(1): 21-22.
- Cho WC and Leung KN (2007). *In vitro* and *in vivo* anti-tumor effects of Astragalus membranaceus. *Cancer Lett.*, **252**(1): 43-54.
- Delaunoit T (2011). Latest developments and emerging treatment options in the management of stomach cancer. *Cancer Manag. Res.*, **3**: 257-266.
- Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS and Duarte A (2010). Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. *BMC. Cancer*, **10**: 641.
- Duan P, Wang ZM (2002). Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor. *Zhongguo. Zhong. Xi. Yi. Jie. He. Za. Zhi.*, **22**(7): 515-517.
- Ezzati M, Henley SJ, Lopez AD and Thun MJ (2005). Role of smoking in global and regional cancer epidemiology: current patterns and data needs. *Int. J. Cancer*, **116**(6): 963-971.
- Gamero AM, Young HA and Wiltrott RH (2004). Inactivation of Stat3 in tumor cells: Releasing a brake on immune responses against cancer? *Cancer Cell*, **5**(2): 111-112.
- Ghafourian Boroujerdnia M, Azemi ME, Hemmati AA, Taghian A and Azadmehr A (2011). Immunomodulatory effects of Astragalus gypsiculus hydroalcoholic extract in ovalbumin-induced allergic mice model. *Iran J. Allergy Asthma Immunol.*, **10**(4): 281-288.
- Giraud AS, Menheniott TR and Judd LM (2012). Targeting STAT3 in gastric cancer. *Expert. Opin. Ther. Targets*, **16**(9): 889-901.
- He Y, Du M, Gao Y, Liu H, Wang H, Wu X and Wang Z (2013). Astragaloside IV attenuates experimental autoimmune encephalomyelitis of mice by counteracting oxidative stress at multiple levels. *PLoS. One.*, **8**(10): e76495.
- Hsu KW, Hsieh RH, Huang KH, Fen-Yau Li A, Chi CW, Wang TY, Tseng MJ, Wu KJ and Yeh TS (2012). Activation of the Notch1/STAT3/Twist signaling axis promotes gastric cancer progression. *Carcinogenesis*. **33**(8): 1459-1467.
- Jackson CB and Giraud AS (2009). STAT3 as a prognostic marker in human gastric cancer. *J. Gastroenterol. Hepatol.*, **24**(4): 505-507.
- Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, Sekikawa A, Kawada M, Suzuki K, Kayahara T, Fukui H, Sawada M and Chiba T (2004). STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. *Oncogene*. **23**(28): 4921-4929.
- Kim DY, Cha ST, Ahn DH, Kang HY, Kwon CI, Ko KH, Hwang SG, Park PW, Rim KS and Hong SP (2009). STAT3 expression in gastric cancer indicates a poor prognosis. *J. Gastroenterol. Hepatol.*, **24**(4): 646-651.
- Kinoshita H, Hirata Y, Nakagawa H, Sakamoto K, Hayakawa Y, Takahashi R, Nakata W, Sakitani K, Serizawa T, Hikiba Y, Akanuma M, Shibata W, Maeda S and Koike K (2013). Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis. *PLoS. One.*, **8**(4): e60914.
- Ko JK, Lam FY and Cheung AP (2005). Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis. *World J. Gastroenterol.*, **11**(37): 5787-5794.
- Krasteva I, Nikolova I, Danchev N and Nikolov S (2004). Phytochemical analysis of ethyl acetate extract from Astragalus corniculatus Bieb. and brain antihypoxic activity. *Acta. Pharm.*, **54**(2): 151-156.
- Lee H, Lee JH, Jung KH and Hong SS (2010). Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer. *Oncol. Rep.*, **24**(4): 957-963.
- Lei H, Wang B, Li WP, Yang Y, Zhou AW and Chen MZ (2003). Anti-aging effect of astragalosides and its mechanism of action. *Acta. Pharmacol. Sin.*, **24**(3): 230-234.
- Leu CM, Wong FH, Chang C, Huang SF and Hu CP (2003). Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. *Oncogene*. **22**(49): 7809-7818.

- Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, Li J, Wang X and Song L (2010). Unregulated miR-96 induces cell proliferation in human breast cancer by down regulating transcriptional factor FOXO3a. *PLoS. One.*, **5**(12): e15797.
- Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM and Kuo ML (2007). IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. *Int. J. Cancer*, **120**(12): 2600-2608.
- Liu J, Chen HB, Guo BL, Zhao ZZ, Liang ZT and Yi T (2011). Study of the relationship between genetics and geography in determining the quality of Astragali Radix. *Biol. Pharm. Bull.*, **34**(9): 1404-1412.
- Liu M, Qin J, Hao Y, Liu M, Luo J, Luo T and Wei L (2013). Astragalus polysaccharide suppresses skeletal muscle myostatin expression in diabetes: Involvement of ROS-ERK and NF-kappaB pathways. *Oxid. Med. Cell Longev.*, p.782497.
- Ma XQ, Shi Q, Duan JA, Dong TT and Tsim KW (2002). Chemical analysis of Radix Astragali (Huangqi) in China: A comparison with its adulterants and seasonal variations. *J. Agric Food Chem.*, **50**(17): 4861-4866.
- Na D, Liu FN, Miao ZF, Du ZM and Xu HM (2009). Astragalus extract inhibits destruction of gastric cancer cells to mesothelial cells by anti-apoptosis. *World J. Gastroenterol.*, **15**(5): 570-577.
- Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H (2002). Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. *Oncogene.*, **21**(13): 2000-2008.
- Park DJ, Thomas NJ, Yoon C and Yoon SS (2015). Vascular endothelial growth factor A inhibition in gastric cancer. *Gastric Cancer*. **18**(1): 33-42.
- Qiao L and Wong BC (2009). Targeting apoptosis as an approach for gastrointestinal cancer therapy. *Drug Resist Updat.*, **12**(3): 55-64.
- Qu ZH, Yang ZC, Chen L, Lv ZD, Yi MJ and Ran N (2012). Inhibition airway remodeling and transforming growth factor-beta1/Smad signaling pathway by astragalus extract in asthmatic mice. *Int. J. Mol. Med.*, **29**(4): 564-568.
- Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM and Fernandez-Luna JL (2002). Resistance to chemotherapy via Stat3-dependent over expression of Bcl-2 in metastatic breast cancer cells. *Oncogene.*, **21**(50): 7611-7618.
- Sekikawa A, Fukui H, Fujii S, Ichikawa K, Tomita S, Imura J, Chiba T and Fujimori T (2008). REG Ialpha protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells. *Carcinogenesis*. **29**(1): 76-83.
- Sinclair S (1998). Chinese herbs: A clinical review of Astragalus, Ligusticum, and Schizandrae. *Altern. Med. Rev.*, **3**(5): 338-344.
- Tao L, Yang JK, Gu Y, Zhou X, Zhao AG, Zheng J and Zhu YJ (2015). Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model. *World J. Gastroenterol.*, **21**(4): 1125-1139.
- Tin MM, Cho CH, Chan K, James AE and Ko JK (2007). Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft. *Carcinogenesis*. **28**(6): 1347-1355.
- Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiwa K, Tsuneyoshi M and Tanaka M (2003). Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. *Cancer Lett.*, **201**(1): 107-116.
- Wang T, Xuan X, Li M, Gao P, Zheng Y, Zang W and Zhao G (2013). Astragalus saponins affect proliferation, invasion and apoptosis of gastric cancer BGC-823 cells. *Diagn. Pathol.*, **8**: 179.
- Wang Z, Li W, Meng X and Jia B (2012). Resveratrol induces gastric cancer cell apoptosis via reactive oxygen species, but independent of sirtuin1. *Clin. Exp. Pharmacol. Physiol.*, **39**(3): 227-232.
- Wang Z, Si X, Xu A, Meng X, Gao S, Qi Y, Zhu L, Li T, Li W and Dong L (2013). Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. *PLoS. One.* **8**(10): e75788.
- Wiita AP, Ziv E, Wiita PJ, Urisman A, Julien O, Burlingame AL, Weissman JS and Wells JA (2013). Global cellular response to chemotherapy-induced apoptosis. *Elife.*, **2**: e01236.
- Wu K, Nie Y, Guo C, Chen Y, Ding J and Fan D (2009). Molecular basis of therapeutic approaches to gastric cancer. *J. Gastroenterol. Hepatol.*, **24**(1): 37-41.
- Wu YL, Sun B, Zhang XJ, Wang SN, He HY, Qiao MM, Zhong J and Xu JY (2001). Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells. *World J. Gastroenterol.*, **7**(6): 796-800.
- Xiong H, Du W, Wang JL, Wang YC, Tang JT, Hong J and Fang JY (2012). Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. *J. Mol. Med. (Berl.)*, **90**(9): 1037-1046.
- Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K and Sekine I (2007). Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. *Int. J. Oncol.*, **30**(2): 437-442.
- Yang ZC, Qu ZH, Yi MJ, Wang C, Ran N, Xie N, Fu P, Feng XY, Lv ZD and Xu L (2013). Astragalus extract attenuates allergic airway inflammation and inhibits nuclear factor kappaB expression in asthmatic mice. *Am. J. Med. Sci.*, **346**(5): 390-395.
- Yin YY, Li WP, Gong HL, Zhu FF, Li WZ and Wu GC (2010). Protective effect of astragaloside on focal cerebral ischemia/reperfusion injury in rats. *Am. J. Chin. Med.*, **38**(3): 517-527.

- Yu H, Pardoll D and Jove R (2009). STATs in cancer inflammation and immunity: A leading role for STAT3. *Nat. Rev. Cancer*, **9**(11): 798-809.
- Zheng Z, Liu D, Song C, Cheng C and Hu Z (1998). Studies on chemical constituents and immunological function activity of hairy root of *Astragalus membranaceus*. *Chin J. Biotechnol.*, **14**(2): 93-97.
- Zhu BH, Chen HY, Zhan WH, Wang CY, Cai SR, Wang Z, Zhang CH and He YL (2011). (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. *World J. Gastroenterol.*, **17**(18): 2315-2325.
- Zhu Q, Zhang X, Zhang L, Li W, Wu H, Yuan X, Mao F, Wang M, Zhu W, Qian H and Xu W (2014). The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. *Cell Death Dis.*, **5**: e1295.